<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Vulto-van Silfhout AT</submitter><funding>Sigrid Julius foundation</funding><funding>van Leersum fonds</funding><funding>max planck innovation funds</funding><funding>Dutch Brain Foundation</funding><funding>Foundation for the National Institutes of Health</funding><funding>German ministry of education and researech (MRNET)</funding><funding>Polish Ministry of Science and Higher Education</funding><funding>NCI NIH HHS</funding><funding>Netherlands Organisation for Health Research and Development</funding><funding>European Commission</funding><funding>Wellcome Trust</funding><funding>NIGMS NIH HHS</funding><pagination>106-17</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4608231</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>36(1)</volume><pubmed_abstract>Variants in cullin 4B (CUL4B) are a known cause of syndromic X-linked intellectual disability. Here, we describe an additional 25 patients from 11 families with variants in CUL4B. We identified nine different novel variants in these families and confirmed the pathogenicity of all nontruncating variants. Neuroimaging data, available for 15 patients, showed the presence of cerebral malformations in ten patients. The cerebral anomalies comprised malformations of cortical development (MCD), ventriculomegaly, and diminished white matter volume. The phenotypic heterogeneity of the cerebral malformations might result from the involvement of CUL-4B in various cellular pathways essential for normal brain development. Accordingly, we show that CUL-4B interacts with WDR62, a protein in which variants were previously identified in patients with microcephaly and a wide range of MCD. This interaction might contribute to the development of cerebral malformations in patients with variants in CUL4B.</pubmed_abstract><journal>Human mutation</journal><pubmed_title>Variants in CUL4B are associated with cerebral malformations.</pubmed_title><pmcid>PMC4608231</pmcid><funding_grant_id>917-86-319</funding_grant_id><funding_grant_id>2009(2)-81</funding_grant_id><funding_grant_id>FP6 037627</funding_grant_id><funding_grant_id>100140</funding_grant_id><funding_grant_id>GM067113</funding_grant_id><funding_grant_id>R01 GM067113</funding_grant_id><funding_grant_id>907-00-365</funding_grant_id><funding_grant_id>R01 CA068377</funding_grant_id><funding_grant_id>FP7 241995</funding_grant_id><funding_grant_id>NN407133739</funding_grant_id><pubmed_authors>Vissers LE</pubmed_authors><pubmed_authors>Yntema HG</pubmed_authors><pubmed_authors>Avela K</pubmed_authors><pubmed_authors>Charzewska A</pubmed_authors><pubmed_authors>Nillesen WM</pubmed_authors><pubmed_authors>Busche A</pubmed_authors><pubmed_authors>Lenart J</pubmed_authors><pubmed_authors>Poirier K</pubmed_authors><pubmed_authors>Kleefstra T</pubmed_authors><pubmed_authors>Raymond FL</pubmed_authors><pubmed_authors>Nawara M</pubmed_authors><pubmed_authors>Mathijssen IB</pubmed_authors><pubmed_authors>Xiong Y</pubmed_authors><pubmed_authors>Haas SA</pubmed_authors><pubmed_authors>Philips AK</pubmed_authors><pubmed_authors>Brunner HG</pubmed_authors><pubmed_authors>Tzschach A</pubmed_authors><pubmed_authors>Lebrun N</pubmed_authors><pubmed_authors>Willemsen MA</pubmed_authors><pubmed_authors>Chelly J</pubmed_authors><pubmed_authors>Vulto-van Silfhout AT</pubmed_authors><pubmed_authors>Amram D</pubmed_authors><pubmed_authors>Fischer U</pubmed_authors><pubmed_authors>Bahi-Buisson N</pubmed_authors><pubmed_authors>Kalscheuer VM</pubmed_authors><pubmed_authors>Baumer A</pubmed_authors><pubmed_authors>Rump P</pubmed_authors><pubmed_authors>Rauch A</pubmed_authors><pubmed_authors>Vigneron J</pubmed_authors><pubmed_authors>Obersztyn E</pubmed_authors><pubmed_authors>Barkovich AJ</pubmed_authors><pubmed_authors>Bienek M</pubmed_authors><pubmed_authors>Ropers HH</pubmed_authors><pubmed_authors>Doagu F</pubmed_authors><pubmed_authors>Voesenek K</pubmed_authors><pubmed_authors>de Brouwer AP</pubmed_authors><pubmed_authors>Gilissen C</pubmed_authors><pubmed_authors>Somer M</pubmed_authors><pubmed_authors>Jarvela I</pubmed_authors><pubmed_authors>Hu H</pubmed_authors><pubmed_authors>Odent S</pubmed_authors><pubmed_authors>van Bokhoven H</pubmed_authors><pubmed_authors>Nakagawa T</pubmed_authors><pubmed_authors>Musebeck J</pubmed_authors><pubmed_authors>de Vries BB</pubmed_authors></additional><is_claimable>false</is_claimable><name>Variants in CUL4B are associated with cerebral malformations.</name><description>Variants in cullin 4B (CUL4B) are a known cause of syndromic X-linked intellectual disability. Here, we describe an additional 25 patients from 11 families with variants in CUL4B. We identified nine different novel variants in these families and confirmed the pathogenicity of all nontruncating variants. Neuroimaging data, available for 15 patients, showed the presence of cerebral malformations in ten patients. The cerebral anomalies comprised malformations of cortical development (MCD), ventriculomegaly, and diminished white matter volume. The phenotypic heterogeneity of the cerebral malformations might result from the involvement of CUL-4B in various cellular pathways essential for normal brain development. Accordingly, we show that CUL-4B interacts with WDR62, a protein in which variants were previously identified in patients with microcephaly and a wide range of MCD. This interaction might contribute to the development of cerebral malformations in patients with variants in CUL4B.</description><dates><release>2015-01-01T00:00:00Z</release><publication>2015 Jan</publication><modification>2026-05-04T13:50:14.629Z</modification><creation>2026-04-24T03:08:51.529Z</creation></dates><accession>S-EPMC4608231</accession><cross_references><pubmed>25385192</pubmed><doi>10.1002/humu.22718</doi></cross_references></HashMap>